Humana Shares Fall Despite Q2 Earnings Beat as Net Profit Forecast Cut

Humana Inc. (NYSE: HUM) on Wednesday reported second-quarter financial results that exceeded analyst estimates, though the company’s shares fell approximately 9% in premarket trading after it cut its full-year net profit guidance.

Earnings Beat and Cost Control

The health insurer posted an adjusted profit of $7.61 per share for the second quarter, beating the LSEG consensus estimate of $7.22 per share. Quarterly net revenue also surpassed expectations, rising 26.2% year-over-year to $40.87 billion, compared to the anticipated $40.61 billion.

Humana's medical cost ratio (MLR) — the percentage of premiums spent on medical care — was 91.2%, which the company stated was in line with its expectations. This figure was nearly identical to the analyst consensus of 91.19%, suggesting medical costs are being managed as projected.

Revised Outlook Weighs on Shares

Despite the strong quarterly performance, investors focused on the company's revised outlook. While Humana maintained its annual adjusted profit forecast of at least $9 per share, it lowered its net profit forecast to at least $6.52 per share, a significant reduction from the previous estimate of at least $8.36.

Ad

The guidance adjustment comes as investor expectations for the sector have been rising, particularly after larger competitor UnitedHealth Group raised its outlook and demonstrated strong cost controls. Humana's unchanged adjusted forecast and lowered net profit outlook appeared to disappoint the market.

Medicare Advantage Growth Continues

Humana, one of the largest providers of Medicare Advantage (MA) plans, continues to expand its membership in a market facing pressure from rising medical costs and tighter government reimbursement rates. The company reported a 23% increase in its individual MA plan memberships during the quarter.

This growth contrasts with some industry peers who have scaled back their presence in the MA market. Humana reaffirmed its annual membership growth expectations for both its Medicare and Medicaid segments.